Risk of valvular heart disease associated with use of fenfluramine

BMC Cardiovascular Disorders

Gerald I Polukoff¹  Paul N Hopkins¹ 

[1] Cardiology Division, University of Utah School of Medicine, Salt Lake City, USA

关键词: risk;    mitral regurgitation;    aortic regurgitation;    dexfenfluramine;    fenfluramine;   

Others  :  1088616
DOI  :  10.1186/1471-2261-3-5

 received in 2003-01-24, accepted in 2003-06-11,  发布年份 2003

【 摘 要 】

Background

Estimates of excess risk of valvular heart disease among prior users of fenfluramine and dexfenfluramine have varied widely. Two major forms of bias appear to contribute to this variability and also result in a systematic under-estimation of risk. The first, a form of nondifferential misclassification, is the result of including background, prevalent cases among both exposed and unexposed persons in calculations of risk. The second bias results from not considering the relatively short duration of exposure to drugs.

Methods

We examined data from all available echocardiographic studies reporting the prevalence of aortic regurgitation (AR) and mitral regurgitation (MR) among persons exposed to fenfluramine or dexfenfluramine and a suitable control group. We also included one study in which previously existing AR or MR had been excluded. We corrected for background prevalent cases, estimated incidence rates in unexposed persons, and performed a person-years analysis of apparent incidence rates based on exposure time to provide an unbiased estimate of relative risk.

Results

Appearance of new AR was strongly related to duration of exposure (R² = 0.75, p < 0.0001). The summary relative risk for mild or greater AR was 19.6 (95% CI 16.3 – 23.5, p < 0.00001); for moderate or greater MR it was 5.9 (95% CI 4.0 – 8.6, p < 0.00001).

Conclusion

These findings provide strong support for the view that fenfluramine and dexfenfluramine are potent causal factors in the development of both aortic and mitral valvular heart disease.

【 授权许可】

   
2003 Hopkins and Polukoff; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Connolly HM, Crary JL, McGoon M, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588.
• [2]Bowen R, Glicklich A, Khan M, Rasmussen S, Wadden T, Bilstad J, Graham D, Green L, Lumpkin M, O’Neill R, Sobel S, Hubbard VS, Yanovski S, Sopko G: Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations. MMWR 1997, 46:1061-1066.
• [3]Wadden TA, Berkowitz RI, Silvestry F, Vogt RA, St John Sutton MG, Stunkard AJ, Foster GD, Aber JL: The fen-phen finale: a study of weight loss and valvular heart disease. Obes Res 1998, 6:278-284.
• [4]Lepor NE, Gross SB, Daley WL, Samuels BA, Rizzo MJ, Luko SP, Hickey A, Buchbinder NA, Naqvi TZ: Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol 2000, 86:107-110.
• [5]Teramae CY, Connolly HM, Grogan M, Miller F. A., Jr.: Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000, 75:456-461.
• [6]Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR, Blackburn GL: Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999, 34:1153-1158.
• [7]Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT: The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998, 339:713-718.
• [8]Weissman NJ, Tighe J. F., Jr., Gottdiener JS, Gwynne JT: An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998, 339:725-732.
• [9]Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB: Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999, 100:2161-2167.
• [10]Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD: Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999, 74:1191-1197.
• [11]Ryan DH, Bray GA, Helmcke F, Sander G, Volaufova J, Greenway F, Subramaniam P, Glancy DL: Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999, 7:313-322.
• [12]Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL: Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000, 283:1703-1709.
• [13]Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T: Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000, 101:2071-2077.
• [14]Davidoff R, McTiernan A, Constantine G, Davis KD, Balady GJ, Mendes LA, Rudolph RE, Bowen DJ: Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001, 161:1429-1436.
• [15]Palmieri V, Arnett DK, Roman MJ, Liu JE, Bella JN, Oberman A, Kitzman DW, Hopkins PN, Morgan D, de Simone G, Devereux RB: Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. Am J Med 2002, 112:710-715.
• [16]Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE: A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998, 339:719-724.
• [17]Weissman NJ: Appetite suppressants and valvular heart disease. Am J Med Sci 2001, 321:285-291.
• [18]Loke YK, Derry S, Pritchard-Copley A: Appetite suppressants and valvular heart disease - a systematic review. BMC Clin Pharmacol 2002, 2:6. BioMed Central Full Text
• [19]Seghatol FF, Rigolin VH: Appetite suppressants and valvular heart disease. Curr Opin Cardiol 2002, 17:486-492.
• [20]Sachdev M, Miller WC, Ryan T, Jollis JG: Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002, 144:1065-1073.
• [21]Schiller NB: Fen/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't. J Am Coll Cardiol 1999, 34:1159-1162.
• [22]Khan MA, St. Peter JV, Herzog CA: Appetite-suppressant drugs and valvular heart disease [letter]. N Engl J Med 1999, 340:478.
• [23]Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, Douglas PS: Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998, 129:870-874.
• [24]Gardin JM, Weissman NJ, Leung C, Panza JA, Fernicola D, Davis KD, Constantine GD, Reid CL: Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001, 286:2011-2014.
• [25]Weissman NJ, Panza JA, Tighe JF, Gwynne JT: Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:267-273.
• [26]Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ: Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999, 83:897-902.
• [27]Reid CL, Gardin JM, Yunis C, T. Kurosaki, Flack JM: Prevalence and clinical correlates of aortic and mitral regurgitation in a young adult population: The CARDIA Study [abstract]. Circulation 1994, 90 (suppl I):I-282.
• [28]Fleiss JL: Statistical Methods for Rates and Proportions. Second edition. New York, John Wiley & Sons; 1981.
• [29]Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research. Principles and Quantitative Methods. New York, Van Nostrand Reinhold Company, Inc.; 1982.
• [30]Khan LK, Serdula MK, Bowman BA, Williamson DF: Use of prescription weight loss pills among U.S. adults in 1996-1998. Ann Intern Med 2001, 134:282-286.
• [31]Moye LA, Annegers AF: Underestimation of the valvulopathy effect of fenfluramine. J Am Coll Cardiol 2000, 36:1434-1436.
• [32]Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL: The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001, 134:261-266.
• [33]Volmar KE, Hutchins GM: Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 2001, 125:1555-1561.
• [34]Voss LM, Wilson NJ, Neutze JM, Whitlock RM, Ameratunga RV, Cairns LM, Lennon DR: Intravenous immunoglobulin in acute rheumatic fever: a randomized controlled trial. Circulation 2001, 103:401-406.